Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma

International Journal of Cancer

Volumn 132, Issue 5, 2013, Pages 1080-1089

  Zhou, Zheng Jun ^a   Dai, Zhi ^a   Zhou, Shao Lai ^a   Fu, Xiu Tao ^a   Zhao, Yi Ming ^a   Shi, Ying Hong ^a   Zhou, Jian ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

CD44v6; hepatocellular carcinoma; heterogeneous ribonucleoprotein A1; invasion; prognosis

Indexed keywords

CD44V6 ANTIGEN; HETEROGENOUS RIBONUCLEOPROTEIN A1; RIBONUCLEOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIGENS, CD44; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; FOLLOW-UP STUDIES; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84872854484     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27742     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 187-96.
3. Llovet JM, Bruix J,. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-27.
4. Olsen SK, Brown RS, Siegel AB,. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol 2010; 3: 55-66.
5. Han SP, Tang YH, Smith R,. Functional diversity of the hnRNPs: past, present and perspectives. Biochem J 2010; 430: 379-92.
6. Cui H, Wu F, Sun Y, et al. Up-regulation and subcellular localization of hnRNP A2/B1 in the development of hepatocellular carcinoma. BMC Cancer 2010; 10: 356.
7. Tauler J, Zudaire E, Liu H, et al. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res 2010; 70: 7137-47.
8. Zhou J, Nong L, Wloch M, et al. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer 2001; 34: 341-50.
9. Pio R, Zudaire I, Pino I, et al. Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. Cancer Res 2004; 64: 4171-9.
10. Matta A, Tripathi SC, DeSouza LV, et al. Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 2009; 125: 1398-406.
11. Carpenter B, MacKay C, Alnabulsi A, et al. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta 2006; 1765: 85-100.
12. LaBranche H, Dupuis S, Ben-David Y, et al. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nat Genet 1998; 19: 199-202.
13. Hay DC, Kemp GD, Dargemont C, et al. Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription. Mol Cell Biol 2001; 21: 3482-90.
14. Pino I, Pio R, Toledo G, et al. Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer 2003; 41: 131-43.
15. Li S, Xu H, Ding H, et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J Pathol 2009; 218: 327-36.
16. Ushigome M, Ubagai T, Fukuda H, et al. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int J Oncol 2005; 26: 635-40.
17. Ma YL, Peng JY, Zhang P, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009; 8: 4525-35.
18. Matter N, Marx M, Weg-Remers S, et al. Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J Biol Chem 2000; 275: 35353-60.
19. Ghigna C, Moroni M, Porta C, et al. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res 1998; 58: 5818-24.
20. Ponta H, Sherman L, Herrlich PA,. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
21. Brown RL, Reinke LM, Damerow MS, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-74.
22. Endo K, Terada T,. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression and patient survival. J Hepatol 2000; 32: 78-84.
23. Li Y, Tian B, Yang J, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004; 130: 460-8.
24. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
25. Zhang T, Huang XH, Dong L, et al. PCBP-1 regulates alternative splicing of the CD44 gene and inhibits invasion in human hepatoma cell line HepG2 cells. Mol Cancer 2010; 9: 72.
26. Zhou S, Tan C, Dai Z, et al. Tacrolimus enhances the invasion potential of hepatocellular carcinoma cells and promotes lymphatic metastasis in a rat model of hepatocellular carcinoma: involvement of vascular endothelial growth factor-C. Transplant Proc 2011; 43: 2747-54.
27. Yang XR, Xu Y, Yu B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res 2009; 15: 5518-27.
28. Bonnal S, Pileur F, Orsini C, et al. Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA. J Biol Chem 2005; 280: 4144-53.
29. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3.
30. Chen M, Zhang J, Manley JL,. Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res 2010; 70: 8977-80.
31. Ford LP, Wright WE, Shay JW,. A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene 2002; 21: 580-3.
32. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24.
33. Klingbeil P, Marhaba R, Jung T, et al. CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res 2009; 7: 168-79.
34. Orian-Rousseau V, Ponta H,. Adhesion proteins meet receptors: a common theme? Adv Cancer Res 2008; 101: 63-92.